2025
ACoP 2025, Aurora, CO, US
From Data to Parameters: FIVEDB as a Tool for Efficient QSP Model Calibration
Authors: Ekaterina Goryacheva, Anna Kopeykina, Almina Polinova, Violetta Polinova, Nail Gizzatkulov, Oleg Demin
Enhancing QSP Model Creation and Validation with Cytoсon DB: A Standardized Repository for In Vivo Cell and Cytokine Baseline Concentrations
Authors: Vladislav Leonov, Ekaterina Mogilevskaya, Elita Gerasimuk, Nikolay Pervushin, Nail Gizzatkulov, Oleg Demin
JuliaCon Local Paris 2025, France
LikelihoodProfiler.jl: Practical Identifiability and Predictability Analysis in Julia
Authors: Ivan Borisov, Evgeny Metelkin
PAGE 2025, Thessaloniki, Greece
Enhancing QSP Model Creation and Validation with CYTOCON DB: A Standardized Repository for In Vivo Cell and Cytokine Baseline Concentrations
Authors: Vladislav Leonov, Ekaterina Mogilevskaya, Elita Gerasimuk, Nikolay Pervushin, Nail Gizzatkulov, Oleg Demin
LikelihoodProfiler.jl: A Unified Package for Practical Identifiability Analysis and Confidence Intervals Estimation
Authors: Ivan Borisov, Aleksander Demin, Evgeny Metelkin
AACR Annual Meeting 2025, Chicago, Illinois, US
Predicting the starting dose and step-up regimen for first-in-human trial of T-cell engagers using mechanistic mathematical modeling
Authors: Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
Assessing strategies to activate DNAM1 signaling and inhibit the TIGIT/PVRIG axis using mathematical modeling
Authors: Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
Optimization of tarlatamab step-up dosing regimen to mitigate cytokine release syndrome using quantitative systems pharmacology modeling
Authors: Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
2024
ACoP 2024, Phoenix, AZ, US
Mechanistic translational modeling versus minimal anticipated biological effect level approach to predict first-in-human dose for T-cell engagers: HPN536 case study
Authors: Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
FIVEDB as a tool for analysis of in vitro experimental data: cytokine production by primary cells and cell lines
Authors: Ekaterina Goryacheva, Anna Kopeikina, Almina Polinova, Nail Gizzatkulov, Alexander Stepanov, Oleg Demin
Development of QSP model of non-small cell lung cancer and its application to select optimal dose for acasunlimab, a bispecific antibody targeting 4-1BB and PD-L1
Authors: Gaurav Bajaj (1), Alexandra Diakonova (2), Sergey Smirnov (2), Anna Roskoshnaia (2), Ivan Borisov (2), Patricia Garrido Castro (3), Nora Pencheva (3), Maria Jure-Kunkel (1), Beesan Tan (4), Tim Maiwald (4), Manish Gupta (1), Oleg Demin (5), Craig Thalhauser (1)
Affiliation: (1) Genmab, Plainsboro, NJ, USA; (2) InSysBio CY, Paphos, Cyprus; (3) Genmab Utrecht, Netherlands; (4) BioNTech SE, Mainz, Germany; (5) InSysBio UK, Edinburgh, UK
Utilizing PBPK/RO model for description of GEN1042 (BNT312) PK and prediction of trimer level to guide dose selection
Authors: Gaurav Bajaj (1), Dmitry Shchelokov (2), Oleg Demin Jr (2), Homer Adams III (1), Summer Feng (1), Leonid Gibiansky (3), Saskia van der Lee (4), Anandhi Johri (1), Alexander Muik (5), Porntula Panorchan (5), Manish Gupta (1), Oleg Demin (6), Craig Thalhauser (1)
Affiliation: (1) Genmab, Plainsboro, NJ, USA; (2) InSysBio CY, Limassol, Cyprus; (3) QuantPharm LLC, North Potomac, MD, USA; (4) Genmab, Utrecht, The Netherlands; (5) BioNTech SE, Mainz, Germany; (6) InSysBio UK, Edinburgh, UK
Application of identifiability analysis to obtain reliable parameters of the QSP model describing mechanism of action GEN1042 (BNT312) and acasunlimab
Authors: Evgeny Metelkin (1), Ivan Borisov (1), Sergey Smirnov (1), Oleg Demin (2), Gaurav Bajaj (3), Jordan Blum (3), Maria Jure-Kunkel (3), Beesan Tan (4), Tim Maiwald (4), Manish Gupta (3), Craig Thalhauser (3)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) InSysBio UK, Edinburgh, UK; (3) Genmab US, Inc, Plainsboro, NJ, (4) BioNTech SE, Mainz, Germany
Quantitative systems pharmacology model for distinguishing efficacy of anti-CD20 therapy variants in populations of Multiple Sclerosis patients
Authors: Tatiana Karelina, Oleg Demin, Dmitry Gordeev, Mariia Myshkina
Quantitative systems pharmacology modeling of neurotoxicity and cognitive scores in Alzheimer’s disease for prediction of therapy outcomes
Authors: Tatiana Karelina (1), Valeriu Damian (2), Oleg Demin (3), Stepan Lerner (1), Polina Maliukova (1), Mahadevabharath Somayaji (2), Olga Ivanova (1)
Affiliation: (1) InSysBio CY, Paphos, Cyprus; (2) GSK, Collegeville, PA, US; (3) InSysBio UK, Edinburgh, UK
Unraveling Major Inflammatory Cytokines Serum Distribution Patterns in Systemic Lupus Erythematosus Patients: Insights from the CYTOCON Database
Authors: Vladislav Leonov, Ekaterina Mogilevskaya, Elita Gerasimuk, Nikolay Pervushin, Nail Gizzatkulov, Oleg Demin
Mechanistic Modeling Of Surface Molecule Interactions: Impact Of Methodology On CAR-T Cell Dose Predictions
Authors: Ruslan Salimgareev, Oleg Demin Jr, Oleg Demin
SITC 2024, Houston, TX, US
Evaluation of various strategies to unleash DNAM1 signaling and block TIGIT/PVRIG axis
Authors: Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
Mechanistic translational modeling to predict first-in-human dose for T-cell engager: HPN536 case study
Authors: Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
Comparison of receptor occupancy and optimal doses of PD1xCD40 and PDL1xCD40 bispecific antibodies using physiologically based pharmacokinetic modeling
Authors: Alexandra Diakonova, Dmitry Schelokov, Oleg Demin Jr, Oleg Demin
